Integrated Analyses of Copy Number Variations and Gene Expression in Lung Adenocarcinoma

Numerous efforts have been made to elucidate the etiology and improve the treatment of lung cancer, but the overall five-year survival rate is still only 15%. Identification of prognostic biomarkers for lung cancer using gene expression microarrays poses a major challenge in that very few overlapping genes have been reported among different studies. To address this issue, we have performed concurrent genome-wide analyses of copy number variation and gene expression to identify genes reproducibly associated with tumorigenesis and survival in non-smoking female lung adenocarcinoma. The genomic landscape of frequent copy number variable regions (CNVRs) in at least 30% of samples was revealed, and their aberration patterns were highly similar to several studies reported previously. Further statistical analysis for genes located in the CNVRs identified 475 genes differentially expressed between tumor and normal tissues (p<10−5). We demonstrated the reproducibility of these genes in another lung cancer study (p = 0.0034, Fisher's exact test), and showed the concordance between copy number variations and gene expression changes by elevated Pearson correlation coefficients. Pathway analysis revealed two major dysregulated functions in lung tumorigenesis: survival regulation via AKT signaling and cytoskeleton reorganization. Further validation of these enriched pathways using three independent cohorts demonstrated effective prediction of survival. In conclusion, by integrating gene expression profiles and copy number variations, we identified genes/pathways that may serve as prognostic biomarkers for lung tumorigenesis.

[1]  J. Testa,et al.  Chromosomal imbalances in human lung cancer , 2002, Oncogene.

[2]  John Quackenbush,et al.  Genesis: cluster analysis of microarray data , 2002, Bioinform..

[3]  Y. Mechulam,et al.  Eukaryotic and archaeal translation initiation factor 2: A heterotrimeric tRNA carrier , 2010, FEBS letters.

[4]  J. Pouysségur,et al.  The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition , 2007, Oncogene.

[5]  Y. Jeon,et al.  High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  William Pao,et al.  EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. , 2008, The Journal of molecular diagnostics : JMD.

[7]  Y. Shu,et al.  Multicolor fluorescence in situ hybridization and comparative genomic hybridization reveal molecular events in lung adenocarcinomas and squamous cell lung carcinomas. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  Holger Sültmann,et al.  Global gene expression analysis reveals specific patterns of cell junctions in non-small cell lung cancer subtypes. , 2009, Lung cancer.

[9]  I Petersen,et al.  Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer , 2008, Oncogene.

[10]  Chris Sander,et al.  An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors , 2009, Oncogene.

[11]  Yuri Kotliarov,et al.  Correlation analysis between single-nucleotide polymorphism and expression arrays in gliomas identifies potentially relevant target genes. , 2009, Cancer research.

[12]  Wei-Guo Zhu,et al.  A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. , 2003, Human molecular genetics.

[13]  K. Takeuchi,et al.  EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR‐targeting tyrosine kinase inhibitors , 2010, The FEBS journal.

[14]  Yi Zhang,et al.  Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. , 2006, Cancer research.

[15]  Igor Jurisica,et al.  Three-gene prognostic classifier for early-stage non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  V. Papadimitrakopoulou,et al.  The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy. , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  Chi-Ying F. Huang,et al.  Chromosomal aberrations of malignant pleural effusions of lung adenocarcinoma: different cytogenetic changes are correlated with genders and smoking habits. , 2007, Lung cancer.

[18]  Nam Huh,et al.  Prediction of Recurrence-Free Survival in Postoperative Non–Small Cell Lung Cancer Patients by Using an Integrated Model of Clinical Information and Gene Expression , 2008, Clinical Cancer Research.

[19]  A. Hartmann,et al.  (www.interscience.wiley.com) DOI: 10.1002/path.2039 , 2006 .

[20]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[21]  Jianhui Xie,et al.  Negative role of trihydrophobin 1 in breast cancer growth and migration , 2010, Cancer science.

[22]  P. Park,et al.  Discovering statistically significant pathways in expression profiling studies. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Testa,et al.  Chromosome alterations in human small cell lung cancer: frequent involvement of 5q. , 1992, Cancer research.

[24]  Sharon R Grossman,et al.  Integrating common and rare genetic variation in diverse human populations , 2010, Nature.

[25]  H. Sasaki,et al.  PIK3CA gene amplification in Japanese non-small cell lung cancer. , 2007, Lung cancer.

[26]  David Haussler,et al.  Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM , 2010, Bioinform..

[27]  Adam M. Gustafson,et al.  A chronic obstructive pulmonary disease related signature in squamous cell lung cancer. , 2011, Lung cancer.

[28]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[29]  A. Bout,et al.  IL-1/IL-3 gene therapy of non-small cell lung cancer (NSCLC) in rats using ‘cracked’ adenoproducer cells , 1998, Gene Therapy.

[30]  F. Cappuzzo,et al.  Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer , 2009, Oncogene.

[31]  Kenny Q. Ye,et al.  Large-Scale Copy Number Polymorphism in the Human Genome , 2004, Science.

[32]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[33]  John D. Minna,et al.  Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops , 2008, Cancer Prevention Research.

[34]  K. Luh,et al.  Epidemiologic characteristics and multiple risk factors of lung cancer in Taiwan. , 1990, Anticancer research.

[35]  P. Hartel,et al.  Del(5q) Is Associated With Clinical and Histological Parameters in Small Cell Neuroendocrine Lung Carcinoma , 2008, International journal of surgical pathology.

[36]  N. Kikuchi,et al.  Nrf2 protects against pulmonary fibrosis by regulating the lung oxidant level and Th1/Th2 balance , 2010, Respiratory research.

[37]  Huachen Gan,et al.  Trihydrophobin 1 Interacts with PAK1 and Regulates ERK/MAPK Activation and Cell Migration* , 2009, Journal of Biological Chemistry.

[38]  M. Ringnér,et al.  Impact of DNA amplification on gene expression patterns in breast cancer. , 2002, Cancer research.

[39]  S. Wacholder,et al.  Gene Expression Signature of Cigarette Smoking and Its Role in Lung Adenocarcinoma Development and Survival , 2008, PloS one.

[40]  Federico Bussolino,et al.  Integrin signaling and lung cancer , 2010, Cell adhesion & migration.

[41]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[42]  G. Parmigiani,et al.  Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers , 2008, Proceedings of the National Academy of Sciences.

[43]  W. Hahn,et al.  Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. , 2009, Molecular cell.

[44]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  加藤 達哉 A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis , 2005 .

[46]  Christian A. Rees,et al.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[47]  D. Cleveland,et al.  Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis , 2009, Nature Reviews Molecular Cell Biology.

[48]  Chi-Ying F. Huang,et al.  Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme , 2007, BMC Genomics.

[49]  Wim Timens,et al.  Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. , 2009, Lung cancer.

[50]  W. Gerald,et al.  Identification of DOK genes as lung tumor suppressors , 2010, Nature Genetics.

[51]  F. Siannis,et al.  Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[52]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[53]  T. Godfrey,et al.  Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer , 2008, Nucleic acids research.

[54]  Chuhsing Kate Hsiao,et al.  Identification of a Novel Biomarker, SEMA5A, for Non–Small Cell Lung Carcinoma in Nonsmoking Women , 2010, Cancer Epidemiology, Biomarkers & Prevention.